Because I'm happy - positive affect and its predictive value for future disease activity in patients with inflammatory bowel diseases: a retrospective cohort study.

"BML, ML, SBUJ, NB, NK, JW, RvK and PJ have no competing interests to declare.: LB reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap, Calypso, Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma.: PS received consulting fees from Pfizer, Abbvie, Takeda and Janssen-Cilag and travel support from Falk, UCB and Pfizer.: SRV has received consulting fees, speakers honorary and unrestricted research grants from Abbott, Alfasigma, Amgen, Arenapharm, Falk Pharma GmbH, Ferring Pharmaceuticals, Gilead, iQuone, Janssen, MSD, Permamed, Pfizer Inc, Sanofi-Aventis, Takeda, Tillotts, UCB, and Vifor.: JZ reports fees for consulting/advisory board from Abbvie, Janssen and traveling fees from Abbvie, Takeda and Vifor.: GR declares consulting fees from Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; speaker’s honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller; and grants support from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB and Zeller.: BM reports traveling fees from Takeda, Vifor, Gilead and MSD. BM received fees as a speaker from Takeda. BM has served at an advisory board for Gilead, Takeda and BMS. BM has received research grants from MSD and BMS unrelated to the submitted work."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a grant from the Swiss National Science Foundation (SNF) to Gerhard Rogler (the Swiss IBD Cohort) [Grant No. 33CS30-148422]."